Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprolide Injectable Emulsion in premenopausal breast cancer
NCT06449027Phase 3Active, not recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Nov 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide in breast cancer (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Proportion of subjects with E2 levels ≤30 pg/mL at 4-48 weeks. Started Aug 2024; status: active, not recruiting.
02
Drugs
leuprolide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06449027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449027.